Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study
- 1 November 2022
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (4) , 827-833
Abstract
Context: Osteoporosis is becoming a global epidemic in aging societies. Anti-osteoporotic medications can prevent fractures, and their pleiotropic effect on mortality is interesting but not well compared among each other.Objective: To provide real-world evidence on the pleiotropic effect of different anti-osteoporotic medications on all-cause mortality, stratified by fracture site, sex, and age.Methods: This longitudinal population-based postfracture cohort study, included mega-data from subjects ≥40 years of age with osteoporotic fracture who used anti-osteoporotic medications as recorded in Taiwan's National Health Insurance Research Database from 2009 to 2017 and followed until 2018. A multivariate Cox proportional hazards model with immortal time bias was used to assess the relationship between fracture sites and mortality stratified by anti-osteoporosis medication.Results: A total of 46 729 subjects with an average age of 74.45 years (80.0% female) and a mean follow-up period of 4.73 years were enrolled. In the total fracture group, compared with raloxifene and bazedoxifene, we found that alendronate/risedronate (hazard ratio [HR] 0.83; 95% CI, 0.79-0.88), denosumab (HR 0.86; 95% CI, 0.81-0.91), and zoledronic acid (HR 0.78; 95% CI, 0.73-0.84) resulted in significantly lower mortality. Similar trends were observed in the hip, vertebral, or nonhip/nonvertebral fracture groups. Subjects receiving long-acting zoledronic acid showed the lowest mortality in the subanalysis according to sex or age over 65 years.Conclusion: This real-world mega-data study suggests that the usage of osteoporotic medication, especially a long-acting regimen, may lower postfracture mortality.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (TOA-2020-B-01, NCKUH-10909042, NCKUH-11103023, NCKUH-11103054)
- National Cheng Kung University Hospital (A-ER-106-123, B-ER-109-346, B-ER-110-124)
This publication has 29 references indexed in Scilit:
- Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysisAtherosclerosis, 2016
- Bisphosphonates and Glucose Homeostasis: A Population-Based, Retrospective Cohort StudyThe Journal of Clinical Endocrinology & Metabolism, 2015
- Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelateOsteoporosis International, 2013
- Effect of Raloxifene on All-cause MortalityThe American Journal of Medicine, 2010
- Effect of Osteoporosis Treatment on Mortality: A Meta-AnalysisThe Journal of Clinical Endocrinology & Metabolism, 2010
- Limitations of the Randomized Controlled Trial in Evaluating Population-Based Health InterventionsAmerican Journal of Preventive Medicine, 2007
- Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative DataMedical Care, 2005
- Medication Use Patterns for Osteoporosis: An Assessment of Guidelines, Treatment Rates, and Quality Improvement InterventionsMayo Clinic Proceedings, 2005
- The components of excess mortality after hip fractureBone, 2003
- Bisphosphonates and atherosclerosisGeneral Pharmacology: The Vascular System, 2000